000141407 001__ 141407
000141407 005__ 20240229105126.0
000141407 0247_ $$2doi$$a10.18632/oncotarget.25402
000141407 0247_ $$2pmid$$apmid:29861868
000141407 0247_ $$2pmc$$apmc:PMC5982766
000141407 0247_ $$2altmetric$$aaltmetric:43968485
000141407 037__ $$aDKFZ-2018-01913
000141407 041__ $$aeng
000141407 082__ $$a610
000141407 1001_ $$aWennmann, Markus$$b0
000141407 245__ $$aVolumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients.
000141407 260__ $$a[S.l.]$$bImpact Journals LLC$$c2018
000141407 3367_ $$2DRIVER$$aarticle
000141407 3367_ $$2DataCite$$aOutput Types/Journal article
000141407 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1542802724_32105
000141407 3367_ $$2BibTeX$$aARTICLE
000141407 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141407 3367_ $$00$$2EndNote$$aJournal Article
000141407 520__ $$aThe purpose of this study was to improve risk stratification of smoldering multiple myeloma patients, introducing new 3D-volumetry based imaging biomarkers derived from whole-body MRI. Two-hundred twenty whole-body MRIs from 63 patients with smoldering multiple myeloma were retrospectively analyzed and all focal lesions >5mm were manually segmented for volume quantification. The imaging biomarkers total tumor volume, speed of growth (development of the total tumor volume over time), number of focal lesions, development of the number of focal lesions over time and the recent imaging biomarker '>1 focal lesion' of the International Myeloma Working Group were compared, taking 2-year progression rate, sensitivity and false positive rate into account. Speed of growth, using a cutoff of 114mm3/month, was able to isolate a high-risk group with a 2-year progression rate of 82.5%. Additionally, it showed by far the highest sensitivity in this study and in comparison to other biomarkers in the literature, detecting 63.2% of patients who progress within 2 years. Furthermore, its false positive rate (8.7%) was much lower compared to the recent imaging biomarker '>1 focal lesion' of the International Myeloma Working Group. Therefore, speed of growth is the preferable imaging biomarker for risk stratification of smoldering multiple myeloma patients.
000141407 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000141407 588__ $$aDataset connected to CrossRef, PubMed,
000141407 7001_ $$aKintzelé, Laurent$$b1
000141407 7001_ $$aPiraud, Marie$$b2
000141407 7001_ $$aMenze, Bjoern H$$b3
000141407 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b4$$udkfz
000141407 7001_ $$aHofmanninger, Johannes$$b5
000141407 7001_ $$aWagner, Barbara$$b6
000141407 7001_ $$aKauczor, Hans-Ulrich$$b7
000141407 7001_ $$aMerz, Maximilian$$b8
000141407 7001_ $$aHillengass, Jens$$b9
000141407 7001_ $$aLangs, Georg$$b10
000141407 7001_ $$aWeber, Marc-André$$b11
000141407 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.25402$$gVol. 9, no. 38$$n38$$p25254-25264$$tOncoTarget$$v9$$x1949-2553$$y2018
000141407 909CO $$ooai:inrepo02.dkfz.de:141407$$pVDB
000141407 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000141407 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000141407 9141_ $$y2018
000141407 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141407 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141407 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141407 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000141407 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000141407 980__ $$ajournal
000141407 980__ $$aVDB
000141407 980__ $$aI:(DE-He78)C060-20160331
000141407 980__ $$aUNRESTRICTED